Clinical consequences of persistent low level viremia

Autor: Dyner Toby, Cafaro Virginia, Chow Valby

Publikováno v: Retrovirology, Vol 9, Iss Suppl 1, p P34 (2012)

Externí odkaz: https://doaj.org/article/99697666eef844bd8e5b946172f89cef

Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.

Autor: Crombie JL; Dana-Farber Cancer Institute, Boston, MA. Jennifer_Crombie@dfci.harvard.edu., Jacobson CA; Dana-Farber Cancer Institute, Boston, MA., Redd R; Dana-Farber Cancer Institute, Boston, MA., Shouse G; City of Hope National Medical Center, Duarte, CA., Herrera AF; City of Hope National Medical Center, Duarte, CA., Chow VA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA., Gauthier J; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA., Mullane E; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Washington, Seattle, WA., Cahill K; University of Chicago, Chicago, IL., Kline J; University of Chicago, Chicago, IL., Romancik J; Emory University, Atlanta, GA., Cohen JB; Emory University, Atlanta, GA., Saucier A; Dana-Farber Cancer Institute, Boston, MA., Houot R; University Hospital of Rennes, Rennes., Armand P; Dana-Farber Cancer Institute, Boston, MA., Hess B; Hollings Cancer Center, Medical University of South Carolina, Charleston, SC.

Publikováno v: Haematologica [Haematologica] 2023 Dec 01; Vol. 108 (12), pp. 3433-3437. Date of Electronic Publication: 2023 Dec 01.

Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant.

Autor: Ogimi C; Pediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA. ogimi-c@ncchd.go.jp.; Department of Pediatrics, University of Washington, Seattle, WA, USA. ogimi-c@ncchd.go.jp.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. ogimi-c@ncchd.go.jp.; Pediatric Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan. ogimi-c@ncchd.go.jp., Krantz EM; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Golob JL; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Liu C; Department of Pediatrics, University of Washington, Seattle, WA, USA.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Waghmare A; Pediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA.; Department of Pediatrics, University of Washington, Seattle, WA, USA.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Akramoff A; Pediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA., Mallory A; Pediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA., Leisenring WM; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Jerome KR; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA., Chow VA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Division of Medical Oncology, University of Washington, Seattle, WA, USA., Pergam SA; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Medicine, University of Washington, Seattle, WA, USA., Fredricks DN; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.; Department of Medicine, University of Washington, Seattle, WA, USA., Englund JA; Pediatric Infectious Diseases Division, Seattle Children's Hospital, Seattle, WA, USA.; Department of Pediatrics, University of Washington, Seattle, WA, USA., Boeckh M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. mboeckh@fredhutch.org.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. mboeckh@fredhutch.org.; Department of Medicine, University of Washington, Seattle, WA, USA. mboeckh@fredhutch.org.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2022 Dec; Vol. 57 (12), pp. 1765-1773. Date of Electronic Publication: 2022 Sep 05.

Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.

Autor: Chow VA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine., Cassaday RD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Hematology, Department of Medicine., Gooley TA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA., Smith SD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine., Sandmaier BM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine., Green DJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine., Orozco JJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine., Tuazon SA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine., Matesan M; Division of Nuclear Medicine, Department of Radiology, University of Washington, Seattle, WA; and., Fisher DR; Versant Medical Physics & Radiation Safety, Richland, WA., Maloney DG; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine., Press OW; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine., Gopal AK; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.; Division of Medical Oncology, Department of Medicine.

Publikováno v: Blood advances [Blood Adv] 2022 Jan 11; Vol. 6 (1), pp. 37-45.

Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

Autor: Scordo M; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York., Wang TP; Division of Transplantation and Cellular Therapy, University of Miami Miller School of Medicine, Miami, Florida., Ahn KW; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee.; Institute for Health and Equity, Division of Biostatistics, Medical College of Wisconsin, Milwaukee., Chen Y; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee., Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Awan FT; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Miller School of Medicine, Miami, Florida., Chen A; Department of Medicine, Oregon Health and Science University, Portland., Chow VA; Fred Hutchinson Cancer Research Center, Seattle, Washington., Dholaria B; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Epperla N; The James Cancer Hospital and Solove Research Institute, Division of Hematology, Department of Medicine, The Ohio State University, Columbus., Farooq U; Division of Hematology, Oncology and Blood & Marrow Transplantation, University of Iowa Hospitals and Clinics, Iowa City., Ghosh N; Levine Cancer Institute, Department of Hematologic Oncology and Blood Disorders, Atrium Health, Charlotte, North Carolina., Grover N; Department of Medicine, University of North Carolina Hospitals, Chapel Hill., Hamad N; St Vincent's Hospital, Darlinghurst, New South Wales, Australia., Hildebrandt GC; Markey Cancer Center, University of Kentucky, Lexington., Holmberg L; Fred Hutchinson Cancer Research Center, Seattle, Washington., Hong S; Blood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio., Inwards DJ; Division of Hematology, Mayo Clinic, Rochester, Minnesota., Jimenez-Jimenez A; Division of Transplantation and Cellular Therapy, University of Miami Miller School of Medicine, Miami, Florida., Karmali R; Department of Medicine, Northwestern University, Chicago, Illinois., Kenkre VP; Department of Medicine, University of Wisconsin-Madison, Madison., Khimani F; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida., Klyuchnikov E; Department for Stem Cell Transplantation, University Cancer Center, Hamburg, Germany., Krem MM; Markey Cancer Center, University of Kentucky, Lexington., Munshi PN; Department of Medicine, Georgetown University Hospital, Washington, DC., Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston., Prestidge T; Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand., Ramakrishnan Geethakumari P; Lymphoma, BMT and Cellular Therapy Program, University of Texas Southwestern Medical Center, Dallas., Rezvani AR; Division of Blood & Marrow Transplantation, Stanford University, Stanford, California., Riedell PA; Department of Medicine, The University of Chicago Medicine, Chicago, Illinois., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan., Shah NN; Department of Medicine, Medical College of Wisconsin, Milwaukee., Solh M; The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta., Yared JA; Blood & Marrow Transplantation Program, Greenebaum Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of Maryland, Baltimore., Kharfan-Dabaja MA; Division of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida., Herrera A; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California., Hamadani M; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee., Sauter CS; Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Weill Cornell Medical College, New York, New York.

Publikováno v: JAMA oncology [JAMA Oncol] 2021 Jul 01; Vol. 7 (7), pp. 993-1003.